SecBot SecBot
Biotech Drug Report Generated Aug 2, 2026

Fluzone

SNY·Sanofi
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved / marketed (comparator in a completed Phase 3 trial; next-gen flu programs in Phase 2)
Time to market
Already on the market (long-approved seasonal flu vaccine; reformulated annually for new strains)
Why 3/10
Fluzone is already approved and marketed with no pending PDUFA or pivotal readout, the only "catalysts" are routine annual strain-version updates, which are not binary, and it is one product inside a mega-cap ($43/share ADR) portfolio, so no hard dated event in the next ~12 months can drive a large SNY move; per the rubric an approved drug with no pending regulatory decision scores 3-5, and the low concentration argues for 3.
Actionable Insight NEUTRAL

If you want flu-vaccine upside, watch Sanofi's separate next-gen flu programs (Phase 2 mRNA/combination trials NCT06744205, NCT06695117 with results pending), which are different molecules from Fluzone.

Price Chart

Loading chart...

Executive Summary

Fluzone is Sanofi's (Sanofi Pasteur) inactivated seasonal influenza vaccine franchise in the US, spanning standard-dose quadrivalent and the 65+ High-Dose version, a long-approved, marketed product reformulated each year for new flu strains. It is a mature revenue product inside a large-cap pharma, not a binary pipeline bet: no PDUFA, no pivotal readout, and no scheduled hard catalyst for the drug itself in the next 12 months, which caps its share-price impact for SNY.

How It Works

Fluzone is a traditional "killed virus" flu shot: it contains inactivated (dead) influenza virus strains matched to the season's circulating flu, injected into the muscle. The immune system learns to recognize those strains and builds antibodies, so if you're exposed to real flu, your body fights it off. Fluzone High-Dose packs roughly four times the antigen into each shot, designed to provoke a stronger immune response in adults 65 and older, whose immune systems respond more weakly.

Trial Status

Fluzone is a mature approved product, not a pipeline drug. Internal trial data show "Fluzone High Dose" was used as the active comparator/control in a completed Phase 3 Novavax COVID+influenza combination vaccine study (NCT06291857, ~9,320 patients, sponsor Novavax, NVAX). Sanofi separately has Phase 2 influenza programs (e.g., hexavalent mRNA flu vaccine NCT06744205, 1,162 patients, completed 2026-05-22 with results pending; combination COVID/flu studies NCT06695117 and NCT06695130), these are distinct next-gen molecules, not Fluzone itself.

The Two-Sided Case

▲ Bull Case3
Established standard of care: 'Fluzone High Dose' appears as the active comparator in a completed, ~9,320-patient Phase 3 Novavax COVID+flu combination trial (NCT06291857), evidence it is a recognized benchmark flu vaccine.
Sanofi is an active, filing, financially healthy developer, multiple SEC 6-Ks filed in the last 90 days (e.g., 2026-07-30, 2026-07-27), and the ADR trades at $43.08 with an analyst mean price target of $54.61 and 16 Buy/Strong Buy ratings vs 1 Sell.
Sanofi's broader flu franchise is being modernized: Phase 2 next-gen flu/combination trials (NCT06744205 hexavalent mRNA flu, NCT06695117 IIV-HD + COVID combo, NCT06695130) recently completed with results pending, showing ongoing investment around the franchise.
▼ Bear Case3
No hard dated catalyst: the SecBot FDA cache shows zero action rows for 'Fluzone' or 'influenza' in the past 365 days, and no upcoming FDA catalysts/events for SNY in the next 30 days, annual strain swaps are routine, not binary events.
Concentration is tiny: Fluzone is one seasonal vaccine among many products at a mega-cap ($43.08 ADR, 52-week range $40.89-$52.68); even a good or bad flu season moves Sanofi's stock modestly.
Institutional sentiment in the local 13F data was mixed-to-negative for Q2 2026: tracked managers showed trims (ASSETMARK -58.6%, Atria -27.7%, Farther Finance -36.2%) and a near-exit (Private Advisor Group -91.9%) against two doubles, and there were small SEC fails-to-deliver events (~$1.2M-$1.9M) in June-July 2026.

Upcoming Catalysts

  • Routine annual FDA strain-selection/version update ahead of the 2026-27 US flu season (regulatory process, not a share-price binary)
  • Sanofi Phase 2 next-gen flu readouts pending, hexavalent mRNA flu vaccine (NCT06744205, completed 2026-05-22) and COVID/flu combination studies (NCT06695117, NCT06695130), these are different drugs from Fluzone but set the tone for the flu franchise
  • Quarterly earnings: Sanofi 6-K/financial reporting (recent 6-K filed 2026-07-30) for vaccines-division sales commentary

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sanofi 6-K SNY ·Originating report

Sources · 4

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov